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Aims. To determine lymphocyte IRS (IRS1 cells) in HCV patients, correlating it to liver IRS (IRS 1liver) and HOMA-IR. This
study tested the hypothesis that IRS1 cells expression can be used as insulin resistance (IR) marker in HCV-infected patients.
IRS1 cells were not studied before in HCV infection. Materials and Methods. HCV chronically infected patients, naı̈ve, nonobese,
noncirrhotic, and nondiabetic were prospectively included and compared to controls (blood donors). Blood was taken, and
leukocytes were separated. IRS1 was determined by real-time PCR. Liver tissue was obtained from transplant donors as controls.
Results. 41 HCV-positive patients were included, 26 males (60.5%); mean age of 45 (±7.9); 33 (80.5%) from genotype 1. 6 out
of 12 controls were males (50%); mean age was 26.7 (±3.2). There was expression of IRS1 in leukocytes. The median IRS1 cells
(HCV) were 0.061 (0.004 to 0.469); the median IRS 1liver (HCV) was 0.0003 (0.00002 to 0.0186)—lower than in controls (resp.,
P = 0.005 and P = 0.018). HOMA-IR had an inverse correlation with IRS 1liver (P = 0.04). There was no correlation between
IRS1 liver and IRS1 cells (P = 0.930). Conclusions. There was expression of IRS1 in leukocytes. IRS1 cells and IRS1 liver were lower
in HCV patients than in controls.
1. Introduction
Chronic infection with hepatitis C virus (HCV) is an
independent risk factor for developing type 2 diabetes
mellitus (DM) [1–5]. There is a three- to ten-fold increased
risk of HCV infection among diabetic patients in comparison
with different control groups [4]; this appears to be linked to
the development of insulin resistance (IR) [6].
The normal route of entry of glucose into the cell
involves receptor autophosphorylation and subsequent tyro-
sine kinase phosphorylation of insulin receptor substrates
(IRS1/2) (Figure 1) [7]. The IR may be secondary to alter-
native serine phosphorylation, as well as due to factors such
as obesity, metabolic syndrome, systemic inflammation, and
hepatic steatosis, which are sometimes present in patients
with HCV [8].
High levels of viral RNA and advanced liver fibrosis may
be the cause of IR in this population [9]. Moreover, a direct
cytopathic effect of HCV on the expression of IRS1 and IRS2
has been suggested [10, 11], particularly in genotype 3 [12].
Indeed, study of pancreatic beta cells and hepatic expression
of IRS1 and 2 have shown an increase in hepatic expression
of IRS1 and 2 after treatment with interferon and ribavirin
[11].
The expression of IRS1 and 2 in lymphocytes has not
been demonstrated in humans but has been shown in some
animal studies [13, 14]. Impairment of IRS2 expression (but
not in IRS1) in monocyte cells was demonstrated in first-
degree relatives of type 2 DM patients [15] The objective
of this study is to determine the expression of IRS1 in
peripheral leukocytes (IRS1 cells) of HCV-infected patients
and in a control group (blood donors), correlating it with
the expression of IRS1 in the liver (IRS1 liver) and the
presence of insulin resistance. Since HOMA-IR is amenable
to criticism, and hyperinsulinemic euglycemic clamp, which
is the best tool to determine insulin resistance, is difficult
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Figure 1: Mechanisms of insulin resistance (adapted from Science Oxcan et al., 2004). The figure shows both normal and alternative route
of entry of glucose into the cell. With the increase of nonoxidized fatty acids by the liver, there is a change in the mechanism of tyrosine
phosphorylation, and the glucose route of entry into the cell is impaired. Thereafter, intracellular insulin resistance occurs because glucose
cannot enter the cell. The insulin resistance is associated with reduced expression of IRS1 and IRS2. These receptors are proteins of a family
of ligands and molecules that connect insulin receptors to a cascade of reactions that allow entry of glucose into the cell. FFA: free fatty acids,
P-Tyr: tyrosine, PI3-K: phosphatidylinositol kinase, ER: endoplasmic reticulum, JNK: Jun N-terminal kinase, IKKβ: inhibitor of nuclear
factor kappa-b kinase subunit b, PKC: protein kinase C, IRS1 and IRS2: insulin receptor substrates 1 and 2.
to be available in clinical practice, this study tested the
hypothesis that IRS1cells expression can be used as IR marker
in HCV infected patients. Our objective was to determine
lymphocyte IRS (IRS1 cells) in HCV patients, correlating it
to liver IRS (IRS1liver) and HOMA-IR.
2. Methods
The study included treatment-naı̈ve patients between 18
and 60 years of age with chronic HCV infection (ELISA
3 and HCV-RNA PCR confirmed), regardless of amino-
transferase levels and genotype. The exclusion criteria were:
patients with clinical, laboratory, and/or biopsy-proven
liver disease not associated with HCV, obese (body mass
index >30), patients with excessive alcohol consumption
(>40 g/day), DM, pancreatic disease, severe cardiovascular
disease, chronic renal failure in dialysis therapy, malignant
disease, active opportunistic infections, organ transplanted
recipients, pregnancy and/or steroids, immunosuppressant
or lipid-lowering drugs use. This study was approved by the
Ethics Committee of the Hospital de Clinicas de Porto Alegre
(HCPA), and all patients signed an informed consent form.
The readers of the index tests and reference standard were
blinded to the results of the other tests.
After inclusion into the trial, ultrasound-guided liver
biopsies were taken from patients, the samples stained with
hematoxylin-eosin and then evaluated using the METAVIR
score [16]. Patients with stage F0/F1 were grouped as having
minimal/mild fibrosis, while those with scores of F2/F3 were
rated as having significant fibrosis. Patients with cirrhosis
(METAVIR F4) were excluded from the study, as well as those
with METAVIR F3 and formation of nodules (classification
of Ishak F5) [17].
The rate of fibrosis progression was calculated taking into
account the METAVIR score and duration of exposure to
the disease, using the formula: fibrosis/duration of disease
exposure in years.
The degree of insulin resistance was calculated accord-
ing to HOMA-IR (Homeostasis Model Assessment-Insulin
Resistance), using the measurement of insulin and fasting
glucose with the formula: HOMA-IR ={[insulin (mU/mL)×
glucose (mg/dL)]/405}.
Patients with HCV were divided initially according to
genotype and viral load, and then each into two groups,
respectively, genotype 3/nongenotype3, and low viral load
(<400.000 UI/mL)/high viral load (>400.000 UI/mL).
Blood and hepatic tissue samples were collected in two
stages. Upon first consultation, a 12 mL blood sample was
collected in a tube without anticoagulant for subsequent
centrifugation, serum separation, and storage at −80◦C.
A liver biopsy was performed at the next consultation
and in addition to the sample of liver tissue, 8 mL of
blood was collected using an EDTA tube for separation
of leukocytes, as per the manufacturer’s protocol (Ficoll-
Histopaque). The time between the first and second sample
collection did not exceed 60 days. The liver fragment
obtained was immediately frozen in liquid nitrogen and
stored at −80◦C. Flow cytometry was used to assess the pop-
ulation of mononuclear cells isolated. The leukocytes isolated
and the liver fragments were used to evaluate the mRNA
expression of IRS1 by real-time polymerase chain reaction
(real-time PCR). RNA extraction was performed in line with
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manufacturer instructions using the commercial kit RNeasy
mini kit (Qiagen) and was then quantified and its quality
tested by photometric measurement. Only high quality RNA
was used (A260/A280>1.95). Primers for amplification were
obtained from the Harvard Medical School Primer Bank
(http://pga.mgh.harvard.edu/primerbank/). The sequences
used were as follows: for the IRS-1, forward primer 5′-
CTATCCAGCGTACTCCAAAG-3′ and reverse primer 5′-
ACAAGTCTGAATGCTCCACT-3′; for relative quantifica-
tion the beta-microglobulin gene was used. The cDNA syn-
thesis was conducted using the SuperScript III First-Strand
Synthesis SuperMix kit in accordance with manufacturer
instructions (Invitrogen).
The PCRs were performed in a final volume of 25 mL,
containing 1 μM of both primers, 1x Syber Green Supermix
(AppliedBiosystems), and varying amounts of RT product.
Amplification was carried out using the Mx3000P real-time
PCR Stratagene (GE) system, with data being processed by
the fully integrated MX PRO software, using the formula
2ΔΔCt. The program profile used for amplification of the
gene IRS1 was 95◦C for 2 min followed by 45 cycles of
denaturation at 95◦C for 30 s, annealing at 52◦C for 15 s and
extension at 60◦C for 30 s.
2.1. Purification and Sequencing of Amplicons. The amplicons
were purified using the enzymes Exonuclease I (Exo I) and
Shrimp Alkaline Phosphatase (SAP) from GE Healthcare.
After verification in agarose, 3.33 U of each enzyme was
added to 6 uL of the PCR product. Subsequently, the reaction
was heated to 37◦C for 30 minutes and 80◦C for 15 minutes.
The purified PCR product was then quantified in 1.5%
agarose gel for comparison using a Low Mass Reader (Invit-
rogen). Between 45 and 60 ng, DNA was used for sequencing,
together with 1 uL of forward primer and 6 uL water qs. The
same primer was used as for the aforementioned PCR, at a
concentration of 4 pM.
The sequencing of amplicons was performed with an
automated sequencer ABI 310 Genetic Analyser using the
reagent BigDye Terminator v3.1 (Applied Biosystems).
2.2. Analysis of Sequencing. The sequences were analyzed by
the Chromas Lite (Technelysium Pty Ltd.) program to detect
and identify the presence of the same fragment amplification
of cDNA samples obtained from the liver and leukocytes.
Sequences were compared with the reference sequence
PrimerBank ID 5031805a1, (http://pga.mgh.harvard.edu/
cgi-bin/primerbank/displayDetail.cgi?primerID=5031805a1)
available through Nucleotide BLAST (http://blast.ncbi.nlm
.nih.gov/). All sequences were confirmed by reverse se-
quencing of the tape.
Blood samples were collected after 12 hours fasting to
determine blood glucose, adiponectin, insulin, and lipid
profile (total cholesterol, HDL cholesterol, and triglycerides).
Measures of glucose and lipid profile were performed
using UV enzymatic hexokinase with the ADVIA 1800
(Siemens). The plasma insulin was measured by electro-
chemical luminescence using the Roche Modular equipment,
and adiponectin was determined according to the ELISA kit
protocol (Adiponectin Human ELISA Kit, Biosource).
2.3. Statistical Methods. Considering a standard deviation of
100 [18], a significance level of 0.05, and power of 80%, the
sample size necessary in order to detect a difference of 120
units of liver IRS between the HCV and control group was
estimated to be at least 27 subjects (9 controls and 18 patients
with HCV).
The data is expressed as a mean ± SD for variables with
normal distribution. The median and percentiles of 25 and
75 were used for variables with skewed distribution. The
Mann-Whitney test and Spearman’s correlation were used
for analysis of the results for expression of IRS1. The level
of significance adopted was 5%.
This study was conducted at the research center of the
HCPA. Financial support was provided by FIPE (Fundo de
Incentivo à Pesquisa e Eventos) of the HCPA.
3. Results
From 93 potentially eligible HCV patients, 41 were included:
26 were male (60.5%); mean age of 45 (±7.9); 33 (80.5%)
were genotype 1; 1 (2.4%) was genotype 2; 4 (9.8%) were
genotype 3. Of the control group 6 were male (50%) with
a mean age of 26.7 (±3.2), lower than that of patients with
HCV (P < 0.001). Among the 52 patients excluded, 11 were
obese (BMI > 30), 2 had cancer, 15 were cirrhotic, 5 had
DM, 1 had hepatitis B virus, and 3 had excessive alcohol
consumption (>40 g/day).
Table 1 lists the data on glycemic and lipid profiles
for patients with HCV in the study. When comparing
the results with the METAVIR fibrosis scores, the median
insulin was found to be significantly higher in patients with
significant fibrosis in contrast to those with minimal/mild
fibrosis. Similarly, the HOMA-IR was higher in the group
with more advanced fibrosis, but without reaching statistical
significance. In relation to high or low viral load, fasting
glucose was significantly higher in patients with high viral
load.
Using the technique of flow cytometry, a population of
mononuclear cells was identified in 83.6% of the total cells,
of which 73.4% were CD3 lymphocytes. Sequencing of the
product of PCR was carried out to confirm the expression
of IRS1 both in leukocytes and in liver tissue and revealed
total similarity between the sequences amplified with the
cDNA sequence of the IRS1 gene. Expression of IRS1 was
seen in leukocytes in both groups. The median IRS1 cells
in patients were 0.061 (0.004 to 0.469), significantly lower
when compared to controls (P = 0.005). The median for
expression of IRS1 liver 0.0003 (0.00002 to 0.0186) was also
lower in patients (P = 0.018).
Table 2 shows the results of IRS1 and its correlation
with age, insulin resistance (HOMA-IR), viral load, and rate
of progression of fibrosis in patients with hepatitis virus
C. There was an inverse association between age and IRS1
cells, while IRS1liver correlated inversely with HOMA-IR.
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Table 1: Glycemic and lipid profiles of patients with chronic hepatitis C and its correlation with viral load and fibrosis.
Variable General F0/F1 F2/F3 P VL <400000 UI/mL VL >400000 UI/mL P




(mean ± SD) (±2.77) (±2.64) (±2.86) (±2.18) (±2.75)




(mean ± SD) (±11.05) (±10.64) (±11.34) (±4.47) (±11.72)




(median 25th–75th%) (5.83–14.76) (4.96–12.05) (7.53–17.03) (4.74–10.24) (6.32–16.40)




(median 25th–75th%) (1.40–3.78) (1.17–3.00) (1.70–4.62) (1.01–2.44) (1.50–4.09)




(mean ± SD) (±33.29) (±38.68) (±22.29) (±57.60) (±27.68)




(mean ± SD) (±13.06) (±9.60) (±17.07) (±9.37) (±12.35)




(median 25–75th%) (70–123) (69–125.5) (78.50–129) (56–108) (70–123)




(median 25–75th%) (3.85–17) (3.03–16.87) (4.92–17.02) (3.22–15.61) (3.23–19.48)
BMI: body mass index; VL: viral load; F0/F1: minimal/mild fibrosis; F2/F3: significant fibrosis.
Table 2: IRS1 in leukocytes and liver of patients with hepatitis C virus and their correlation.
Variable
IRS1 leukocytes IRS1 liver
(n = 31) (n = 36)
Value Spearman (rho) P Value Spearman (rho) P
Age 44.77 −0.368 0.02 44.89 −0.297 0.07
(mean ± SD) (±8.4) (±7.9)
HOMA-IR 2.63 −0.118 0.55 2.13 −0.341 0.04
(median 25th–75th%) (1.38–3.86) (1.28–3.90)
HCV viral load 1119,225
0.291 0.16
807,000 −0.135 0.44
(median 25th–75th%) (518,280–3107,865) (310,000–3101,797)
Fibrosis F3—2 (6.9%) −0.022 0.91 F3—3 (8.1%) −0.182 0.28
(n/%) F1,2—27 (93.1%) F1,2—34 (91.9%)
Fibrosis progression 0,0006876 −0.030 0.87 0,0006876 −0.187 0.28
(median 25th–75th%) (0.0005–0.00100) (0.0005–0.00100)
There was no correlation between IRS1 cells and IRS1 liver
(Spearman test rho = 0.018 and P = 0.930).
4. Discussion
Although the target organ of infection by the hepatitis C
virus is the liver, the action of this virus becomes increasingly
clear in other organs. Hepatitis C causes more a systemic
disease than just a liver disease. Greater attention has recently
been given to metabolic disorders caused by HCV, firstly
the association with hepatic steatosis and changes in lipid
metabolism [19], and more lately its correlation with insulin
resistance and DM [1–3, 6], and also cardiovascular risk
[20–22]. Hepatitis C can induce a chronic inflammatory
state, and inflammatory cytokines are related to decreased
expression of IRS1 in nonalcoholic fatty liver disease [3, 18,
23–25]. Indeed, a recently published study from our group
[20] demonstrates that HCV patients have increased levels
of proinflammatory cytokines (TNF-α and IL-6) and also
a higher pro-antinflammatory cytokine rate than controls.
This is an important finding since some studies have shown
that the largest proportion of cellular infiltrate found in a
liver with chronic hepatitis C is TH1 cells, such as IL-1b, IL-2,
IL-6, IL-8, TNF-α and IFN [26]. On the other hand, a recent
meta-analysis has demonstrated that sustained virological
response is lower in patients with higher HOMA (>2) [27].
HCV-induced insulin resistance is considered to be more
peripheral than hepatic shown by Milner et al. [28] in 29
nonobese infected patients. By means of (1)H-magnetic res-
onance spectroscopy, authors concluded that HCV induces
predominantly muscle insulin resistance, closely related to
inflammation, independently of visceral obesity and liver fat.
In order to assess the direct role of HCV on the
mechanisms of action of insulin in different areas (leukocytes
and liver tissue), we studied a selected group of patients with
chronic hepatitis C infection. The sample selection is one of
the strengths of this study as the role of the virus could be
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better evaluated in a population without obesity, metabolic
syndrome, DM, cirrhosis, and with no history of previous
antiviral treatment.
To verify the quality of test, the expression of IRS1 in
real-time PCR was confirmed by sequencing of the amplified
fragment, based on the cDNA sequence, demonstrating
that the amplified fragment in the leukocytes is the same
amplified fragment in the liver. The expression of IRS1 in the
leukocytes could facilitate the search for surrogate markers of
IR in evaluating the prognosis of patients with HCV.
There is evidence that HCV itself can induce insulin
resistance through changes in the route of insulin signaling
and the entry of glucose into the cell [1, 9, 18, 29, 30]. This
hypothesis is confirmed in this study by demonstrating the
decrease of IRS1 in patients with HCV as compared with the
control group. The core HCV proteins have a direct cyto-
pathic action on the insulin signaling pathway by decreasing
the expression of IRS1, altering the normal route of tyrosine
phosphorylation, and entry of glucose into the cell.
The decreased expression of IRS that seems to be
downregulated by the HCV is an important step in the
development of IR. Studies have shown that genotype 1
is strongly associated with increased insulin resistance [9,
31], but there are evidences of IR in hepatitis C patients
with any genotypes [9]. Most of the included patients in
the present study were infected by HCV genotype 1. In
the present study, when considered the whole population,
patients had no increase in HOMA-IR. Only patients with
significant fibrosis had an abnormal test. This is the opposite
of the results published by Vanni et al. In their study, also
focusing lean and nondiabetic patients, insulin resistance,
determined by clamp, was not related to liver fibrosis [18].
On the other hand, in our study, IRS1 was decreased in the
whole population and was not influenced by the severity
of fibrosis. These findings may suggest that IRS1 decrease
is an initial event in this process. An inverse correlation
between the expression of IRS1 liver and HOMA-IR was
shown in our study, and this is in agreement with the
findings demonstrated in liver tissue by Kawaguchi et al.
[11]. This study also showed that patients who achieved
a sustained virologic response to treatment displayed a
decrease in HOMA-IR and HOMA-β, in addition to an
increased expression of IRS1 and 2 in the hepatocytes. In
agreement with these results, Huang et al. recently showed
that sustained virological response can improve glucose
abnormalities in prediabetic patients with chronic HCV
infection [32].
Two studies in animals have demonstrated the expression
of IRS1 in leukocytes [13, 14] the first, using a one dog and
one cat, evaluated by PCR the expression of IRS1 and IRS2,
PI3-K, P-85α in different tissues responsive to insulin and in
peripheral leukocytes. The aim was to investigate differences
in expression of markers found in both species. Authors
showed that there is a significant decrease in expression of
IRS1, IRS2, PI3-K, P-85α in cats as compared to dogs, but
they did not address the difference between these markers in
tissues like liver, muscle, adipocytes, and leukocytes. In our
study, IRS1 both in cells and in the liver was lower in HCV
patients than controls, but there was no correlation between
the different sites. The second study conducted by the same
group cited above used nine dogs when investigating how
much an intensive treatment controlling blood glucose levels
could cause changes in peripheral leukocytes. Using the same
markers as evaluated in the first study, it showed there was
a significant increase in IRS1, IRS2, PI3-K, P-85α after treat-
ment, and thus the observed changes in peripheral leukocytes
were regarded as an improvement in glucose metabolism
after treatment with insulin. In addition, the leukocytes
were considered sufficiently sensitive enough to monitor
the improvement of glycemic control during the intensive
treatment therapy of insulin in dogs with DM. Authors con-
sidered that insulin has a strong regulatory function in leuko-
cytes and emphasized that these cells are far more accessible
and easier to obtain than other insulin sensitive tissues. Our
study found decreased expression of IRS1 in both liver tissue
and in isolated leukocytes. This is found to be unprecedented
in HCV patients and opens a new perspective in relation to
the evaluation of insulin resistance. Accessibility to a test that
can feasibly use peripheral blood in comparison to the use of
a liver biopsy encourages us to develop new tools to assist in
the monitoring of these patients. Perhaps, it would be better
in the future to compare IRS1cells to hyperinsulinemic-
euglycemic clamp in order to really establish its utility as a
surrogate marker of insulin resistance.
In conclusion, selected treatment-naı̈ve, nonobese, non-
cirrhotic, nondiabetic patients with HCV presented a lower
expression of IRS1 both in leukocytes and in the liver,
and this may be related to the commencement of insulin
resistance. IRS1 is inversely correlated with HOMA-IR,
which in turn is increased in patients with advanced fibrosis.
This study demonstrated the expression of IRS1 in HCV
patients for the first time. Further studies are needed to
determine whether the leukocyte expression of IRS1 may be
used as a substitute marker for liver tissue expression.
Abbreviations
BMI: Body mass index
DM: Diabetes mellitus
HCV: Hepatitis C virus
HOMA-IR: Homeostasis model assessment-insulin
resistance
IR: Insulin resistance
IRS: Insulin resistance substrate
PCR: Polymerase chain reaction.
Disclosure
The authors of this study confirm that they have no
commercial associations that pose a conflict of interests in
connection with this paper.
References
[1] S. Aytug, D. Reich, L. E. Sapiro, D. Bernstein, and N. Begum,
“Impaired IRS-1/PI3-kinase signaling in patients with HCV:
a mechanism for increased prevalence of type 2 diabetes,”
Hepatology, vol. 38, no. 6, pp. 1384–1392, 2003.
6 International Journal of Hepatology
[2] J. M. Hui, A. Sud, G. C. Farrell et al., “Insulin resistance is
associated with chronic hepatitis C and virus infection fibrosis
progression,” Gastroenterology, vol. 125, no. 6, pp. 1695–1704,
2003.
[3] F. Negro and M. Alaei, “Hepatitis C virus and type 2 diabetes,”
World Journal of Gastroenterology, vol. 15, no. 13, pp. 1537–
1547, 2009.
[4] A. Lonardo, L. E. Adinolfi, S. Petta, A. Craxi, and P. Loria,
“Hepatitis C and diabetes: the inevitable coincidence?” Expert
Review of Anti-Infective Therapy, vol. 7, no. 3, pp. 293–308,
2009.
[5] A. Lonardo, N. Carulli, and P. Loria, “HCV and diabetes. A
two-question-based reappraisal,” Digestive and Liver Disease,
vol. 39, no. 8, pp. 753–761, 2007.
[6] C. Garcı́a-Monzón, O. Lo Iacono, R. Mayoral et al., “Hepatic
insulin resistance is associated with increased apoptosis and
fibrogenesis in nonalcoholic steatohepatitis and chronic hep-
atitis C,” Journal of Hepatology, vol. 54, no. 1, pp. 142–152,
2011.
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